Why the study?
Does the CYP2D6*4 polymorphism affect heart rate and blood pressure in beta-blocker users?
Does the CYP2D6*4 polymorphism affect heart rate and blood pressure in beta-blocker users?
CYP2D6 poor metabolizers using beta-blockers, particularly metoprolol, have significantly lower heart rates and an increased risk of bradycardia compared to extensive metabolizers.
No takes yet. Share an insight, caveat, or question.
May increase bradycardia risk in CYP2D6 poor metabolizers on metoprolol; leaves open whether genotyping improves outcomes.
Bijl et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: